Go to the list of all blogs
Harry Richardson's Avatar
published in Blogs
Jul 08, 2019
Healthcare ETF trending lower and gets a bearish signal

Healthcare ETF trending lower and gets a bearish signal

The healthcare sector has been lagging the nine other main sectors since the beginning of 2019. The Healthcare Select Sector SPDR (NYSE: XLV) gained 9.24% from the beginning of the year through July 5 and it is the only sector SPDR that has gained less than 10%. The sector has been in the political spotlight to some degree as politicians on both sides of the aisle have been pointing at drug costs as a problem.

One particular exchange-traded fund that caught my eye was the iShares Nasdaq Biotechnology ETF (Nasdaq: IBB). The fund has been trending lower since last September and there is a trend line that connects the highs from then with highs from March and April. The fund just hit the trend line last week and then turned lower.

The ETF saw its 10-day RSI and its daily stochastic readings hit overbought levels last week before turning lower. The stochastic readings just made a bearish crossover on July 5.

The Tickeron Trend Prediction Engine generated a bearish signal for the IBB on July 5 and it calls for a decline of at least 4% within the next month. The signal showed a confidence level of 75% and past predictions on the fund have been successful 85% of the time.

Related Ticker: XLV

Contributor

Harry Richardson — Algorithmic Trader & Strategy Developer Harry is an algorithmic trader specializing in impulse and breakout trading strategies across cryptocurrency and equity markets. With more than 10 years of experience in developing automated trading systems, he focuses on building structured algorithms designed to capture momentum while maintaining strict risk control. His approach combines quantitative analysis, real-market execution, and continuous performance monitoring. Vitalii prioritizes risk management, drawdown control, and strategy stability over short-term optimization, ensuring algorithms are adaptable to changing market conditions. He has developed and tested hundreds of automated strategies, working extensively with live trading environments, forward testing, and portfolio-level algorithm management. His work centers on transforming trading ideas into fully operational, scalable automated systems.


XLV in upward trend: price expected to rise as it breaks its lower Bollinger Band on September 08, 2026

XLV may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 34 of 41 cases where XLV's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 83%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 38 of 54 cases where XLV's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 70%.

The Momentum Indicator moved above the 0 level on October 09, 2026. You may want to consider a long position or call options on XLV as a result. In 72 of 97 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 74%.

The Moving Average Convergence Divergence (MACD) for XLV just turned positive on October 09, 2026. Looking at past instances where XLV's MACD turned positive, the stock continued to rise in 39 of 49 cases over the following month. The odds of a continued upward trend are 80%.

XLV moved above its 50-day moving average on October 09, 2026 date and that indicates a change from a downward trend to an upward trend.

Following a +0.82% 3-day Advance, the price is estimated to grow further. Considering data from situations where XLV advanced for three days, in 267 of 327 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where XLV declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.

The Aroon Indicator for XLV entered a downward trend on September 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Notable companies

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), ABBVIE (NYSE:ABBV), Merck & Co (NYSE:MRK), Unitedhealth Group (NYSE:UNH), Amgen (NASDAQ:AMGN), Gilead Sciences (NASDAQ:GILD), Abbott Laboratories (NYSE:ABT), Pfizer (NYSE:PFE), Intuitive Surgical (NASDAQ:ISRG).

Industry description

The investment seeks investment results that, before expenses, correspond generally to the price and yield performance of publicly traded equity securities of companies in the Health Care Select Sector Index. In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies from the following industries: pharmaceuticals; health care equipment & supplies; health care providers & services; biotechnology; life sciences tools & services; and health care technology. The fund is non-diversified.

Market Cap

The average market capitalization across the State Street Health Care Select Sector SPDR ETF (XLV) ETF is 107.05B. The market cap for tickers in the group ranges from 9.23B to 1.06T. LLY holds the highest valuation in this group at 1.06T. The lowest valued company is PODD at 9.23B.

High and low price notable news

The average weekly price growth across all stocks in the State Street Health Care Select Sector SPDR ETF (XLV) ETF was 3%. For the same ETF, the average monthly price growth was 3%, and the average quarterly price growth was 17%. MRNA experienced the highest price growth at 18%, while COO experienced the biggest fall at -4%.

Volume

The average weekly volume growth across all stocks in the State Street Health Care Select Sector SPDR ETF (XLV) ETF was -5%. For the same stocks of the ETF, the average monthly volume growth was 15% and the average quarterly volume growth was 14%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 39
P/E Growth Rating: 41
Price Growth Rating: 38
SMR Rating: 58
Profit Risk Rating: 74
Seasonality Score: 23 (-100 ... +100)
View a ticker or compare two or three
XLV
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Category Health

Category
Health
Address
One Lincoln Street Cph0326Boston
Phone
N/A
Web
www.spdrs.com
Interact to see
Advertisement
The Bitwise Solana Staking ETF (BSOL) advanced roughly 18% over the trailing 30 days, closely tracking a sharp rally in Solana (SOL). The move extends a broader recovery, with BSOL up approximately 77% over the past three months from its mid-2026 trough.
MSTY is an actively managed single-stock option income ETF (exchange-traded fund) that writes call options on Strategy (MSTR), formerly MicroStrategy, to generate current income. The portfolio is anchored by U.S. Treasury bills and MSTR option contracts rather than a diversified basket of equities, concentrating exposure in one volatile underlying.
AMDL has surged roughly +64% over the past 30 days, from about $47.59 to $78.10, mirroring a powerful rally in its sole underlying stock, AMD . The fund is a leveraged single-stock ETF (exchange-traded fund) designed to deliver 2x the daily return of AMD, amplifying both gains and losses.
TSMX, a 2x daily leveraged single-stock ETF (exchange-traded fund), rose roughly +19% over the trailing 30 days, rebounding sharply from mid-September lows. The fund seeks 200% of the daily return of TSM (Taiwan Semiconductor Manufacturing), meaning its moves are roughly double the underlying stock's daily swings.
Contracted revenue anchor: A roughly $3.2 billion, seven-year LNG (liquefied natural gas) supply agreement with Puerto Rico has received final approval, providing multi-year cash-flow visibility if execution stays on track. Project pipeline inflection: Upcoming milestones include the Barcarena and PortoCem power plants in Brazil, a potential Gás Sul terminal restart, and optimization of the company's modular "Fast LNG" (FLNG) liquefaction fleet.
AMD (Advanced Micro Devices) designs central processing units (CPUs), graphics processing units (GPUs), and AI accelerators, while LRCX (Lam Research) supplies the wafer-fabrication equipment used to build advanced chips. AMD has delivered strong double-digit revenue growth on AI data-center demand, but its shares trade with elevated expectations that can trigger sharp reactions around earnings.
Origination momentum: Velocity Financial enters 2026 off record annual originations of roughly $2.7 billion (up about 48%), positioning it to keep gaining share in a fragmented investor-loan market. Credit normalization is the central watch item: Nonperforming loans fell toward the 8.5% range of portfolio unpaid principal balance (UPB), but asset quality remains the primary swing factor for earnings.
Turnaround milestone ahead: Management has pointed to reaching cash generation in 2027, making the pace of cost discipline and margin recovery the central question for the stock forecast. Fresh capital supports execution: A recently announced $45.5 million equity financing, with participation from management and a single institutional investor, strengthens the balance sheet as the company funds its transformation.
NFE closed at $5.51, down -6.13% during Tuesday's regular session, extending a slide that has pushed shares near a 52-week low. Primary catalyst: the company disclosed its Fast LNG unit is offline after a gas-turbine mechanical failure, with return to service not expected until Q4.
The central $11 target is the arithmetic mean of four verified analyst price targets, rounded from roughly $10.75. With the stock near $2.06, reaching $11 would require an upside of more than 400%, an extremely large move.
The $23 central target is the rounded arithmetic mean of four verified analyst price targets, which average $23.25. The latest verified price is around $9.57, meaning the target implies roughly 140% upside—a very large move.
NXH closed down -11.17% (-$0.23) to $1.83 on Oct 6, the most recent regular session, extending a steep two-day decline. Selling continued as investors digested the mutual termination of the Fathom Holdings merger and a dilutive $45.5M registered direct offering of ~16.5M shares at $2.76.
AMD is a large-cap designer of CPUs (central processing units) and GPUs (graphics processing units) competing directly with Nvidia in the AI accelerator market, while FORM is a small-cap provider of semiconductor test and measurement equipment, primarily probe cards. AMD's narrative has been driven by multi-billion-dollar hyperscaler deals, while FORM's has been powered by record revenue and sharp margin expansion tied to high-bandwidth memory (HBM) demand.
AMD has surged roughly 200% year to date, crossing a $1 trillion market capitalization on AI data-center demand and a "CPU renaissance" narrative. KLAC has gained about 71% year to date, supported by record process-control revenue and rapid growth in advanced packaging for AI chips.
AMD is a large-cap semiconductor designer riding explosive AI compute demand, while ENTG is a mid-cap supplier of materials and purity solutions that feed the same AI-driven chip cycle. AMD recently crossed a $1 trillion market capitalization on surging data center revenue, whereas ENTG operates at a far smaller scale (roughly $23 billion) with steadier, double-digit growth.
VELO closed Tuesday at $9.57, unchanged (+0.00%) from the prior session, with the move occurring during regular market hours. The flat close marked stabilization after Monday's -14.5% plunge, when shares fell to $9.57 from $11.20 following disclosure of CFO James Suva's departure.
The $8 target used here is a technical, publicly discussed recovery objective — not an analyst consensus — because legacy analyst price targets were set before NFE's restructuring and reverse stock split. New Fortress Energy Inc. ( NFE ) trades near $5.51, so reaching $8 implies a roughly 45% advance.
AVBP plunged -46.98% during Tuesday's regular session, closing at $15.09 versus $28.46, marking its worst single-day decline on record. The catalyst was the Phase 3 FURVENT trial of firmonertinib failing its primary endpoint—progression-free survival—in first-line EGFR exon 20 insertion non-small cell lung cancer.
Upcoming catalyst: The company's next earnings release is estimated for November 6, 2026, which should offer fresh detail on its SKY token holdings, staking rewards, and treasury strategy. Strategic positioning: SDEV is an on-chain holding company providing public-market exposure to the Sky protocol ecosystem, with SKY as its core digital asset and a stated focus on the stablecoin economy.
Different roles in the chip ecosystem: AMAT is a materials-engineering and deposition leader, while KLAC dominates process control, inspection, and yield management. Momentum favors AMAT: AMAT shares have more than doubled this year, while KLAC has recently pulled back roughly 9% in a month on margin and execution concerns.